Efficacy and Safety of Dupilumab for COPD with Type 2 Inflammation Indicated by Elevated Eosinophils

作者
Surya Prakash Bhatt,Henrik Watz,Klaus Friedrich Rabe,NA Hanania,Claus Franz Vogelmeier,J Cole,Mona Bafadhel,Stephanie A. Christenson,Alberto A. Papi,Dave Singh,Elizabeth Laws,Xin Lu,D Bauer,Eric R. Mortensen,Jennifer M. Maloney,Ashish Bansal,Loleth E. Robinson,Raolat M. Abdulai
出处
期刊:Pneumologie [Thieme Medical Publishers (Germany)]
标识
DOI:10.1055/s-0044-1781407
摘要

Introduction: Dupilumab (DPL), a fully human mAb, blocks the shared receptor component for IL-4 and IL-13, key/central drivers of Type 2 (T2) inflammation. The objective is to determine efficacy/safety in patients with moderate-to-severe COPD with T2 inflammation. Methods: BOREAS (NCT03930732) was a 52-week (wk), phase 3, randomized, double-blind, placebo (PBO)-controlled trial of efficacy/safety of biweekly DPL 300mg in COPD pts with blood eosinophils ≥300cells/µL at screening, on triple therapy (an inhaled corticosteroid [ICS], long-acting β2-agonists [LABA], and long-acting muscarinic antagonists [LAMA]; or LABA/LAMA if ICS was contraindicated) without asthma diagnosis/history. Primary endpoint: annualized rate of moderate-severe exacerbations. Secondary/other endpoints: change from baseline (BL) in pre-bronchodilator FEV 1 at wk 12 and wk 52; cumulative exacerbations over time; safety. Results: 939 participants were randomized to PBO (N=471) or DPL (N=468). DPL reduced exacerbation rates by 30% vs PBO (p=0.0005). DPL significantly increased pre-BD FEV 1 at wk 12 (LSM difference vs PBO: 83mL, p<0.0001); sustained through wk 52 (83mL, p=0.0003). This trended towards reduced exacerbation-associated annualized total SCS treatment duration for DPL (13.57 days [SD 13.17] vs for PBO (19.09 days [SD 20.65]). Safety similar in DPL and PBO groups; TEAEs balanced. Conclusions: DPL significantly improved moderate-severe exacerbations, lung function, quality of life, and symptoms in COPD patients with T2 inflammation. The use of SCS days required for the treatment of AECOPD trended lower with DPL. Acknowledgments: *PD Dr. Henrik Watz is presenting on behalf of the original authors. Data first presented at the European Respiratory Society International Congress (ERS 2023); Milan, Italy; September 9-13, 2023. Research was sponsored by Sanofi and Regeneron Pharmaceuticals Inc. Medical writing/editorial assistance was provided by Luke Ray, Ph.D., of Excerpta Medica, and was funded by Sanofi and Regeneron Pharmaceuticals Inc., according to the Good Publication Practice guidelines . Publication History Article published online: 01 March 2024 © 2024. Thieme. All rights reserved. Georg Thieme Verlag Rüdigerstraße 14, 70469 Stuttgart, Germany

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
黄家宝发布了新的文献求助10
刚刚
wu完成签到,获得积分10
1秒前
年轻孤萍完成签到,获得积分10
1秒前
will发布了新的文献求助10
1秒前
超级苹果完成签到,获得积分10
1秒前
小圆子完成签到,获得积分10
1秒前
阿狸a完成签到,获得积分10
2秒前
null的应助被科研通管家采纳,获得10
2秒前
超越俗尘完成签到,获得积分10
2秒前
英姑的应助被科研通管家采纳,获得10
2秒前
linlin完成签到,获得积分10
2秒前
Hello的应助被科研通管家采纳,获得10
2秒前
等待的鸡翅完成签到,获得积分10
2秒前
慕青的应助被科研通管家采纳,获得10
2秒前
小果儿完成签到,获得积分10
2秒前
chen发布了新的文献求助10
2秒前
哈哈w发布了新的文献求助10
2秒前
称心的谷菱完成签到 ,获得积分10
3秒前
zhiruiwang完成签到,获得积分10
3秒前
针真滴完成签到 ,获得积分10
3秒前
斯文败类的应助被细腻驳采纳,获得10
3秒前
sunshine完成签到,获得积分10
3秒前
苹果听枫完成签到,获得积分10
3秒前
4秒前
黎谱完成签到,获得积分10
4秒前
Liu完成签到,获得积分10
5秒前
5秒前
satellite完成签到,获得积分10
5秒前
十一完成签到 ,获得积分10
5秒前
Ujana完成签到,获得积分10
5秒前
一叶知秋完成签到,获得积分10
6秒前
star完成签到 ,获得积分10
6秒前
神勇初瑶完成签到,获得积分10
6秒前
seedcode完成签到,获得积分10
6秒前
6秒前
李爱国的应助被呋喃采纳,获得10
6秒前
结果诠释过往完成签到 ,获得积分10
7秒前
Maestro_S的应助被黄家宝采纳,获得10
8秒前
冷酷以山完成签到,获得积分10
8秒前
gxiaxia完成签到,获得积分10
9秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1500
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
Analyses de reconnaissances de dettes passées devant les échevins d'Ypres (1249-1291) 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8159212
求助须知:如何正确求助?哪些是违规求助? 9554678
关于积分的说明 21720538
捐赠科研通 7748887
什么是DOI,文献DOI怎么找? 3427184
关于科研通互助平台的介绍 2552092
邀请新用户注册赠送积分活动 2471464